^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMC128

    i
    Other names: BMC128, BMC-128, BMC 128
    Associations

    News

    Trials
    Company:
    Evogene
    Drug class:
    Microbiome modulator
    Related drugs:
    Associations

    News

    Trials
    11ms
    BMC128-001: A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Biomica Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR wild-type • ALK wild-type
    |
    Opdivo (nivolumab) • BMC128
    over1year
    BMC128-001: A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 (clinicaltrials.gov)
    P1, N=12, Recruiting, Biomica Ltd. | Trial completion date: May 2023 --> Nov 2025 | Trial primary completion date: Feb 2023 --> Apr 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR wild-type • ALK wild-type
    |
    Opdivo (nivolumab) • BMC128